Garassino, Marina Chiara <br/><br/>
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.  [electronic resource] 

 -  The Lancet. Oncology  Sep 2013 
 - 981-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(13)70310-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Disease-Free Survival<br/>Docetaxel<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Quinazolines--therapeutic use<br/>Taxoids--therapeutic use<br/>ras Proteins--genetics